{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:33:00Z","timestamp":1793046780560,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Johns Hopkins Center for Psychedelic and Consciousness Research"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Psychedelic-assisted therapy (PAT) with substances like psilocybin and MDMA has shown promise for conditions including depression and post-traumatic stress disorder. Psilocybin and MDMA may become approved medicines in the coming decade. This study assessed knowledge and attitudes regarding PAT among 879 U.S. healthcare professionals via anonymous online survey. Multivariable linear regression was used to identify predictors of openness to clinical use. Most participants (71.2%) were female and White (85.8%), with a mean (SD) age of 45.5 (12.7) years. Registered nurses (25.4%) and physicians (17.7%) comprised the largest professional groups. Respondents endorsed strong belief in therapeutic promise, and moderate openness to clinical use and support for legal access to both substances, with higher overall ratings for psilocybin compared to MDMA. Objective knowledge items revealed low knowledge of therapeutic uses, risks, and pharmacology. Primary concerns were lack of trained providers, financial cost, and potential contraindications. Prior psychedelic use, self-rated knowledge, younger age, and professional role predicted openness to clinical use of psilocybin and MDMA, with physicians reporting lower openness. As psychedelics continue to garner popular and scientific interest, results indicate a pressing need for additional formal training to provide balanced, evidence-based information from trusted sources.<\/jats:p>","DOI":"10.1038\/s41598-024-78736-1","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T10:07:04Z","timestamp":1731578824000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among U.S. healthcare professionals"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1042-2541","authenticated-orcid":false,"given":"Erin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Mathai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Gukasyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2182-1644","authenticated-orcid":false,"given":"Albert","family":"Garcia-Romeu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,14]]},"reference":[{"key":"78736_CR1","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.pharmthera.2003.11.002","volume":"101","author":"DE Nichols","year":"2004","unstructured":"Nichols, D. E. Hallucinogens.\u00a0Pharmacol. Ther. 101, 131\u2013181 (2004).","journal-title":"Pharmacol. Ther."},{"key":"78736_CR2","doi-asserted-by":"publisher","first-page":"901","DOI":"10.2147\/RMHP.S300656","volume":"14","author":"RG dos Santos","year":"2021","unstructured":"dos Santos, R. G., Bouso, J. C., Rocha, J. M., Rossi, G. N. & Hallak, J. E. The Use of Classic Hallucinogens\/Psychedelics in a therapeutic context: Healthcare Policy opportunities and challenges. Risk Manag Healthc. Policy. 14, 901\u2013910 (2021).","journal-title":"Risk Manag Healthc. Policy"},{"key":"78736_CR3","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nrn3530","volume":"14","author":"DJ Nutt","year":"2013","unstructured":"Nutt, D. J., King, L. A. & Nichols, D. E. Effects of schedule I drug laws on neuroscience research and treatment innovation. Nat. Rev. Neurosci. 14, 577\u2013585 (2013).","journal-title":"Nat. Rev. Neurosci."},{"key":"78736_CR4","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","volume":"384","author":"R Carhart-Harris","year":"2021","unstructured":"Carhart-Harris, R. et al. Trial of Psilocybin versus Escitalopram for Depression. N Engl. J. Med. 384, 1402\u20131411 (2021).","journal-title":"N Engl. J. Med."},{"key":"78736_CR5","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","volume":"387","author":"GM Goodwin","year":"2022","unstructured":"Goodwin, G. M. et al. Single-dose psilocybin for a treatment-resistant episode of Major Depression. N Engl. J. Med. 387, 1637\u20131648 (2022).","journal-title":"N Engl. J. Med."},{"key":"78736_CR6","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2023.14530","volume":"330","author":"CL Raison","year":"2023","unstructured":"Raison, C. L. et al. Single-dose psilocybin treatment for major depressive disorder: a Randomized Clinical Trial. JAMA. 330, 843\u2013853 (2023).","journal-title":"JAMA"},{"key":"78736_CR7","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","volume":"30","author":"S Ross","year":"2016","unstructured":"Ross, S. et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J. Psychopharmacol. (Oxf). 30, 1165\u20131180 (2016).","journal-title":"J. Psychopharmacol. (Oxf)"},{"key":"78736_CR8","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","volume":"30","author":"RR Griffiths","year":"2016","unstructured":"Griffiths, R. R. et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J. Psychopharmacol. (Oxf). 30, 1181\u20131197 (2016).","journal-title":"J. Psychopharmacol. (Oxf)"},{"key":"78736_CR9","unstructured":"FDA Grants Breakthrough Therapy. Designation for MDMA-Assisted therapy for PTSD, agrees on Special Protocol Assessment for Phase 3 trials. Multidisciplinary Association Psychedelic Stud. (2017)."},{"key":"78736_CR10","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","volume":"27","author":"JM Mitchell","year":"2021","unstructured":"Mitchell, J. M. et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat. Med. 27, 1025\u20131033 (2021).","journal-title":"Nat. Med."},{"key":"78736_CR11","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1177\/0269881114565144","volume":"29","author":"MP Bogenschutz","year":"2015","unstructured":"Bogenschutz, M. P. et al. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J. Psychopharmacol. (Oxf). 29, 289\u2013299 (2015).","journal-title":"J. Psychopharmacol. (Oxf)"},{"key":"78736_CR12","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/0269881114548296","volume":"28","author":"MW Johnson","year":"2014","unstructured":"Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. & Griffiths, R. R. Pilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction. J. Psychopharmacol. (Oxf). 28, 983\u2013992 (2014).","journal-title":"J. Psychopharmacol. (Oxf)"},{"key":"78736_CR13","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1177\/0269881121991792","volume":"35","author":"B Sessa","year":"2021","unstructured":"Sessa, B. et al. First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder. J. Psychopharmacol. (Oxf). 35, 375\u2013383 (2021).","journal-title":"J. Psychopharmacol. (Oxf)"},{"key":"78736_CR14","doi-asserted-by":"publisher","first-page":"104793","DOI":"10.1016\/j.neubiorev.2022.104793","volume":"140","author":"M Van Elk","year":"2022","unstructured":"Van Elk, M. & Yaden, D. B. Pharmacological, neural, and psychological mechanisms underlying psychedelics: a critical review. Neurosci. Biobehav Rev. 140, 104793 (2022).","journal-title":"Neurosci. Biobehav Rev."},{"key":"78736_CR15","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1176\/appi.ajp.2019.19010035","volume":"177","author":"CM Reiff","year":"2020","unstructured":"Reiff, C. M. et al. Psychedelics and psychedelic-assisted psychotherapy. Am. J. Psychiatry. 177, 391\u2013410 (2020).","journal-title":"Am. J. Psychiatry"},{"key":"78736_CR16","first-page":"279","volume":"7","author":"SW Wheeler","year":"2020","unstructured":"Wheeler, S. W. & Dyer, N. L. A systematic review of psychedelic-assisted psychotherapy for mental health: an evaluation of the current wave of research and suggestions for the future. Psychol. Conscious. Theory Res. Pract. 7, 279\u2013315 (2020).","journal-title":"Psychol. Conscious. Theory Res. Pract."},{"key":"78736_CR17","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1080\/09540261.2018.1486289","volume":"30","author":"A Garcia-Romeu","year":"2018","unstructured":"Garcia-Romeu, A. & Richards, W. A. Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions. Int. Rev. Psychiatry Abingdon Engl. 30, 291\u2013316 (2018).","journal-title":"Int. Rev. Psychiatry Abingdon Engl."},{"key":"78736_CR18","unstructured":"MDMA-Assisted Therapy Receives a Complete Response Letter From the FDA. AJMC (2024). https:\/\/www.ajmc.com\/view\/mdma-assisted-therapy-receives-a-complete-response-letter-from-the-fda"},{"key":"78736_CR19","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1097\/NMD.0000000000000828","volume":"206","author":"BS Barnett","year":"2018","unstructured":"Barnett, B. S., Siu, W. O. & Pope, H. G. A survey of American psychiatrists\u2019 attitudes toward Classic Hallucinogens. J. Nerv. Ment Dis. 206, 476\u2013480 (2018).","journal-title":"J. Nerv. Ment Dis."},{"key":"78736_CR20","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1080\/02791072.2021.1957183","volume":"54","author":"BS Barnett","year":"2022","unstructured":"Barnett, B. S., Beaussant, Y., King, F. & Doblin, R. Psychedelic knowledge and opinions in psychiatrists at two Professional conferences: an exploratory survey. J. Psychoact. Drugs. 54, 269\u2013277 (2022).","journal-title":"J. Psychoact. Drugs"},{"key":"78736_CR21","unstructured":"Lewis, K. Perspectives of MSW Students towards the use and research of hallucinogenic drugs within a clinical mental health setting. (2019)."},{"key":"78736_CR22","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1002\/jcad.12429","volume":"100","author":"BG Hearn","year":"2022","unstructured":"Hearn, B. G., Brubaker, M. D. & Richardson, G. Counselors\u2019 attitudes toward psychedelics and their use in therapy. J. Couns. Dev. 100, 364\u2013373 (2022).","journal-title":"J. Couns. Dev."},{"key":"78736_CR23","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1080\/02791072.2021.1971343","volume":"54","author":"AK Davis","year":"2022","unstructured":"Davis, A. K., Agin-Liebes, G., Espa\u00f1a, M., Pilecki, B. & Luoma, J. Attitudes and beliefs about the therapeutic use of psychedelic drugs among psychologists in the United States. J. Psychoact. Drugs. 54, 309\u2013318 (2022).","journal-title":"J. Psychoact. Drugs"},{"key":"78736_CR24","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1556\/2054.2023.00294","volume":"8","author":"A Wells","year":"2024","unstructured":"Wells, A., Fernandes, M. & Reynolds, L. Perceptions and attitudes towards psychedelic-assisted psychotherapy among health professionals, patients, and the public: a systematic review. J. Psychedelic Stud. 8, 43\u201362 (2024).","journal-title":"J. Psychedelic Stud."},{"key":"78736_CR25","doi-asserted-by":"publisher","first-page":"114727","DOI":"10.1016\/j.psychres.2022.114727","volume":"316","author":"TD Meyer","year":"2022","unstructured":"Meyer, T. D., Meir, P., Lex, C. & Soares, J. C. Magic mushrooms \u2013 an exploratory look at how mental health professionals feel and think about Psilocybin. Psychiatry Res. 316, 114727 (2022).","journal-title":"Psychiatry Res."},{"key":"78736_CR26","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1007\/s11845-021-02668-2","volume":"1971-191","author":"K Corrigan","year":"2022","unstructured":"Corrigan, K. et al. Psychedelic perceptions: mental health service user attitudes to psilocybin therapy. Ir. J. Med. Sci. 1971-191, 1385\u20131397 (2022).","journal-title":"Ir. J. Med. Sci."},{"key":"78736_CR27","unstructured":"Cullen, D. The therapeutic application of MDMA: Knowledge and attitudes of psychologists in Aotearoa."},{"key":"78736_CR28","unstructured":"Brittany Dawn Rudolph. Knowledge, Attitudes, and Beliefs About Ketamine as an Antidepressant Among Providers. (2020)."},{"key":"78736_CR29","unstructured":"Weisman, J. A. Systematic Review of Medical Students\u2019 and Professionals\u2019 Attitudes and Knowledge Regarding Medical Cannabis as a Proxy for Forecasting Trends in the Medical Community\u2019s Acceptance of Therapeutic Hallucinogens."},{"key":"78736_CR30","doi-asserted-by":"publisher","first-page":"107102","DOI":"10.1016\/j.yebeh.2020.107102","volume":"109","author":"M Szaflarski","year":"2020","unstructured":"Szaflarski, M. et al. Attitudes and knowledge about cannabis and cannabis-based therapies among US neurologists, nurses, and pharmacists. Epilepsy Behav. 109, 107102 (2020).","journal-title":"Epilepsy Behav."},{"key":"78736_CR31","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12875-019-0906-y","volume":"20","author":"LM Philpot","year":"2019","unstructured":"Philpot, L. M., Ebbert, J. O. & Hurt, R. T. A survey of the attitudes, beliefs and knowledge about medical cannabis among primary care providers. BMC Fam Pract. 20, 17 (2019).","journal-title":"BMC Fam Pract."},{"key":"78736_CR32","doi-asserted-by":"publisher","first-page":"8160","DOI":"10.3390\/ijerph18158160","volume":"18","author":"LM Reynolds","year":"2021","unstructured":"Reynolds, L. M. et al. Cancer Healthcare workers\u2019 perceptions toward psychedelic-assisted therapy: a preliminary investigation. Int. J. Environ. Res. Public. Health. 18, 8160 (2021).","journal-title":"Int. J. Environ. Res. Public. Health"},{"key":"78736_CR33","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s40596-022-01662-9","volume":"47","author":"WL Prueitt","year":"2023","unstructured":"Prueitt, W. L. & Sloshower, J. Psychedelic Medicine: creating an Introductory Course for Mental Health Professionals and trainees. Acad. Psychiatry. 47, 74\u201377 (2023).","journal-title":"Acad. Psychiatry"},{"key":"78736_CR34","unstructured":"Grant Supports Development of Training for Psychiatrists in Psychedelic Medicine. https:\/\/medicine.yale.edu\/news-article\/grant-supports-development-of-training-for-psychiatrists-in-psychedelic-medicine\/"},{"key":"78736_CR35","unstructured":"Psychedelic Therapy Training Program. https:\/\/pttp.socialwork.columbia.edu\/"},{"key":"78736_CR36","unstructured":"The Science of Psychedelics. Research, Risks, and therapeutic potentials. https:\/\/www.apa.org https:\/\/www.apa.org\/education-career\/ce\/science-psychedelics"},{"key":"78736_CR37","unstructured":"Explore Sessions on Clinical Updates at the. 2023 APA Annual Meeting. https:\/\/www.psychiatry.org:443\/Explore-Sessions-on-Clinical-Updates"},{"key":"78736_CR38","doi-asserted-by":"publisher","first-page":"1040217","DOI":"10.3389\/fpsyt.2022.1040217","volume":"13","author":"CA MacCallum","year":"2022","unstructured":"MacCallum, C. A., Lo, L. A., Pistawka, C. A. & Deol, J. K. Therapeutic use of psilocybin: practical considerations for dosing and administration. Front. Psychiatry. 13, 1040217 (2022).","journal-title":"Front. Psychiatry"},{"key":"78736_CR39","unstructured":"Ruse, J. M., Jerome, L., Mithoefer, M. C., Doblin, R. & Gibson, E. MDMA-Assisted Psychotherapy for the Treatment of Posttraumatic Stress Disorder."},{"key":"78736_CR40","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/0269881108093587","volume":"22","author":"M Johnson","year":"2008","unstructured":"Johnson, M., Richards, W. & Griffiths, R. Human hallucinogen research: guidelines for safety. J. Psychopharmacol. Oxf. Engl. 22, 603\u2013620 (2008).","journal-title":"J. Psychopharmacol. Oxf. Engl."},{"key":"78736_CR41","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jad.2022.06.036","volume":"312","author":"DS Mathai","year":"2022","unstructured":"Mathai, D. S. et al. Mapping consent practices for outpatient psychiatric use of ketamine. J. Affect. Disord. 312, 113\u2013121 (2022).","journal-title":"J. Affect. Disord"},{"key":"78736_CR42","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.neuropharm.2018.05.012","volume":"142","author":"MW Johnson","year":"2018","unstructured":"Johnson, M. W., Griffiths, R. R., Hendricks, P. S. & Henningfield, J. E. The abuse potential of medical psilocybin according to the 8 factors of the controlled substances Act. Neuropharmacology. 142, 143\u2013166 (2018).","journal-title":"Neuropharmacology"},{"key":"78736_CR43","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.jad.2024.05.131","volume":"361","author":"DS Mathai","year":"2024","unstructured":"Mathai, D. S., Hull, T. D., Vando, L. & Malgaroli, M. At-home, telehealth-supported ketamine treatment for depression: findings from longitudinal, machine learning and symptom network analysis of real-world data. J. Affect. Disord. 361, 198\u2013208 (2024).","journal-title":"J. Affect. Disord"},{"key":"78736_CR44","doi-asserted-by":"publisher","first-page":"204512532311715","DOI":"10.1177\/20451253231171512","volume":"13","author":"VWL Tsang","year":"2023","unstructured":"Tsang, V. W. L., Tao, B., Dames, S., Walsh, Z. & Kryskow, P. Safety and tolerability of intramuscular and sublingual ketamine for psychiatric treatment in the roots to thrive ketamine-assisted therapy program: a retrospective chart review. Ther. Adv. Psychopharmacol. 13, 20451253231171512 (2023).","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"78736_CR45","doi-asserted-by":"crossref","unstructured":"Hughes, M. E. & Garcia-Romeu, A. Ethnoracial inclusion in clinical trials of psychedelics: a systematic review. eClinicalMedicine 74, (2024).","DOI":"10.1016\/j.eclinm.2024.102711"},{"key":"78736_CR46","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1001\/jamapsychiatry.2022.4101","volume":"80","author":"JS Siegel","year":"2023","unstructured":"Siegel, J. S., Daily, J. E., Perry, D. A. & Nicol, G. E. Psychedelics Drug Legislative Reform ant legalization in the US. JAMA Psychiatry. 80, 77\u201383 (2023).","journal-title":"JAMA Psychiatry"},{"key":"78736_CR47","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.amjmed.2021.07.033","volume":"135","author":"MP Lamkin","year":"2022","unstructured":"Lamkin, M. P. & Psychedelics The Road from FDA approval to clinical practice. Am. J. Med. 135, 15\u201316 (2022).","journal-title":"Am. J. Med."},{"key":"78736_CR48","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1037\/pha0000084","volume":"24","author":"A Garcia-Romeu","year":"2016","unstructured":"Garcia-Romeu, A., Kersgaard, B. & Addy, P. H. Clinical applications of Hallucinogens: a review. Exp. Clin. Psychopharmacol. 24, 229\u2013268 (2016).","journal-title":"Exp. Clin. Psychopharmacol."},{"key":"78736_CR49","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1177\/0269881117731279","volume":"32","author":"RR Griffiths","year":"2018","unstructured":"Griffiths, R. R. et al. Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. J. Psychopharmacol. Oxf. Engl. 32, 49\u201369 (2018).","journal-title":"J. Psychopharmacol. Oxf. Engl."},{"key":"78736_CR50","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1093\/ijnp\/pyx047","volume":"20","author":"T Pokorny","year":"2017","unstructured":"Pokorny, T., Preller, K. H., Kometer, M., Dziobek, I. & Vollenweider, F. X. Effect of psilocybin on Empathy and Moral decision-making. Int. J. Neuropsychopharmacol. 20, 747\u2013757 (2017).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"78736_CR51","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/s41398-021-01706-y","volume":"11","author":"MK Doss","year":"2021","unstructured":"Doss, M. K. et al. Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. Transl Psychiatry. 11, 574 (2021).","journal-title":"Transl Psychiatry"},{"key":"78736_CR52","doi-asserted-by":"publisher","DOI":"10.1101\/2023.01.09.523291","author":"A Torrado Pacheco","year":"2023","unstructured":"Torrado Pacheco, A., Olson, R. J., Garza, G. & Moghaddam, B. Acute psilocybin enhances cognitive flexibility in rats. BioRxiv Prepr Serv. Biol. https:\/\/doi.org\/10.1101\/2023.01.09.523291 (2023). 2023.01.09.523291.","journal-title":"BioRxiv Prepr Serv. Biol."},{"key":"78736_CR53","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1080\/02791072.1986.10472362","volume":"18","author":"DE Nichols","year":"1986","unstructured":"Nichols, D. E. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J. Psychoact. Drugs. 18, 305\u2013313 (1986).","journal-title":"J. Psychoact. Drugs"},{"key":"78736_CR54","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1097\/00004714-200008000-00010","volume":"20","author":"J Cami","year":"2000","unstructured":"Cami, J. et al. Human pharmacology of 3,4-methylenedioxymethamphetamine (\u2018ecstasy\u2019): psychomotor performance and subjective effects. J. Clin. Psychopharmacol. 20, 455\u2013466 (2000).","journal-title":"J. Clin. Psychopharmacol."},{"key":"78736_CR55","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.neubiorev.2015.08.016","volume":"57","author":"P Kamilar-Britt","year":"2015","unstructured":"Kamilar-Britt, P. & Bedi, G. The prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA): controlled studies in humans and laboratory animals. Neurosci. Biobehav Rev. 57, 433\u2013446 (2015).","journal-title":"Neurosci. Biobehav Rev."},{"key":"78736_CR56","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/j.1360-0443.2006.01423.x","volume":"101","author":"CA Baylen","year":"2006","unstructured":"Baylen, C. A. & Rosenberg, H. A review of the acute subjective effects of MDMA\/ecstasy. Addict. Abingdon Engl. 101, 933\u2013947 (2006).","journal-title":"Addict. Abingdon Engl."},{"key":"78736_CR57","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1177\/0269881120965915","volume":"35","author":"BJ Illingworth","year":"2021","unstructured":"Illingworth, B. J. et al. A comparison of MDMA-assisted psychotherapy to non-assisted psychotherapy in treatment-resistant PTSD: a systematic review and meta-analysis. J. Psychopharmacol. (Oxf). 35, 501\u2013511 (2021).","journal-title":"J. Psychopharmacol. (Oxf)"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-78736-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-78736-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-78736-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T11:06:25Z","timestamp":1731582385000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-78736-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,14]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["78736"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-78736-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,14]]},"assertion":[{"value":"21 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AGR is a paid scientific advisor to Innerwell and Otsuka Pharmaceutical Development & Commercialization, Inc. All the remaining authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28022"}}